NOTRELOAD AI
  • NOTRELOAD AI
  • Stocks BUZZ.
  • #TrumpTrade
  • 24-HOUR Pass →
  • Invest ↗
Sign in Subscribe

Burlington Shares Tumble Despite Profit Beat as Revenue Disappoints

Burlington Stores (BURL) stock plunges after Q3 revenue miss blamed on warm weather traffic decline, overshadowing earnings beat and raised guidance.

Burlington Shares Tumble Despite Profit Beat as Revenue Disappoints
Credit: Burlington Stores
Already have an account? Sign in.
11/25/2025 · 11:03 AM
BURL
/ Read more

Feed↓

Lilly’s Retatrutide Crushes Weight Loss Goals in First Phase 3 Trial – Wall Street Says It’s a ‘Key Pillar’ for Growth
Featured/ 03/19/2026 · 12:51 PM

Lilly’s Retatrutide Crushes Weight Loss Goals in First Phase 3 Trial – Wall Street Says It’s a ‘Key Pillar’ for Growth

Eli Lilly’s retatrutide delivered up to 2.0% A1C reduction and 16.8% weight loss (36.6 lbs) in its first Phase 3 trial for type 2 diabetes. Analysts call it a key growth driver for Lilly with strong results vs Mounjaro.

/ Subscriber only
Fannie and Freddie Shares Crash: Trump Privatization Dreams Fade Fast
03/19/2026 · 11:56 AM

Fannie and Freddie Shares Crash: Trump Privatization Dreams Fade Fast

Fannie Mae and Freddie Mac shares hit 1-year lows in March, down ~70% in 6 months as investors doubt Trump administration's privatization plans and IPO timeline.

/ Subscriber only
Schizophrenia Focus Pays Off — Canaccord Starts MPLT at Buy, Sees $35 Value on ML-007 Alone
03/19/2026 · 11:02 AM

Schizophrenia Focus Pays Off — Canaccord Starts MPLT at Buy, Sees $35 Value on ML-007 Alone

Canaccord Genuity starts coverage on MapLight Therapeutics (MPLT) with Buy rating and $35 price target.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2025
Email address Subscribe